

PROVECTUS BIOPHARMACEUTICALS, INC.  
Form 8-K  
November 06, 2014

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 6, 2014

PROVECTUS BIOPHARMACEUTICALS, INC.  
(Exact name of registrant as specified in charter)

Delaware  
(State or other jurisdiction  
of incorporation)

001-36457  
(Commission  
File Number)

90-0031917  
(IRS Employer  
Identification No.)

7327 Oak Ridge Hwy., Knoxville, Tennessee  
37931  
(Address of Principal Executive Offices)

(866) 594-5999  
(Registrant's Telephone Number, Including Area  
Code)

(Former Name or Former Address, If Changed  
Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17  
CFR240.13e-4(c))



Item 7.01. Regulation FD Disclosure.

On November 6, 2014, Provectus Biopharmaceuticals, Inc., issued a press release (the “Press Release”) announcing that the abstract titled “Efficacy of Intralesional Injection with PV-10 in Combination with Co-Inhibitory Blockade in a Murine Model of Melanoma,” to be presented at the Society for Immunotherapy of Cancer [SITC] 29th Annual Meeting on Saturday, November 8, 2014, is now available at <http://www.immunotherapyofcancer.org/content/2/S3/P120>. A copy of the Press Release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Pursuant to the rules and regulations of the Securities and Exchange Commission, the information in this Item 7.01 disclosure, including Exhibit 99.1 and information set forth therein, is deemed to have been furnished and shall not be deemed to be “filed” under the Securities Exchange Act of 1934.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number	Description
99.1	Press Release, dated November 6, 2014

---

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 6, 2014

PROVECTUS BIOPHARMACEUTICALS, INC.

By: /s/ Peter R.  
Culpepper  
Peter R. Culpepper  
Chief Financial Officer and Chief Operating Officer

---

EXHIBIT INDEX

Exhibit Number	Description
99.1	Press Release, dated November 6, 2014